Abbott Laboratories beat EPS estimates 95% of the time across 20 reported quarters (19 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $1.28 | $1.31 | +2.3% | Beat |
| Q12026 FY2026 | $1.14 | $1.15 | +0.9% | Beat |
| Q42025 FY2025 | $1.50 | $1.50 | +0.0% | Beat |
| Q42024 FY2024 | $1.34 | $1.34 | +0.0% | Beat |
| Q42023 FY2023 | $1.19 | $1.19 | +0.0% | Beat |
| Q3 FY2023 | $1.10 | $1.14 | +3.6% | Beat |
| Q2 FY2023 | $1.04 | $1.08 | +3.9% | Beat |
| Q1 FY2023 | $0.98 | $1.03 | +5.1% | Beat |
| Q42022 FY2022 | $0.90 | $1.03 | +14.4% | Beat |
| Q32022 FY2022 | $0.91 | $1.15 | +26.4% | Beat |
| Q22022 FY2022 | $1.13 | $1.43 | +26.6% | Beat |
| Q12022 FY2022 | $1.47 | $1.73 | +17.7% | Beat |
Back to ABT overview · ABT holders · ABT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.